Type Condition

Kansas City, MO

156 Clinical Paid Trials near Kansas City, MO

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

S227928 + Venetoclax for Leukemia

Fairway, Kansas
The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this combination. The study will begin as a Phase 1 Dose Escalation study to determine the RP2D and then will transition to a Phase 2 Dose Expansion study to assess the efficacy of the selected RP2D. During the treatment period participants will have study visits every two weeks, with additional visits occurring during the first and second cycle. Approximately 30 days after treatment has ended, an end-of-treatment visit will occur and then participants will be followed for survival every 12 weeks for the next 6 months. Study visits may include a bone marrow aspirate and/or biopsy, blood and urine tests, ECG, vital signs, physical examination, and administration of study treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

132 Participants Needed

Zunsemetinib + Capecitabine for Breast Cancer

Westwood, Kansas
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

152 Participants Needed

AZD0754 for Prostate Cancer

Westwood, Kansas
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Sex:Male

60 Participants Needed

BMS-986458 + Rituximab for Non-Hodgkin Lymphoma

Fairway, Kansas
This trial is testing a new drug called BMS-986458 to see if it is safe and effective for patients whose non-Hodgkin Lymphoma has come back or didn't respond to other treatments. The study will look at how well the drug works alone and with other cancer-fighting drugs.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

308 Participants Needed

DF1001 for Solid Cancers

Westwood, Kansas
This trial is testing a new treatment called DF1001-001 that helps the immune system target and destroy cancer cells. It focuses on patients with certain types of cancers that have a protein called HER2. The treatment works by activating immune cells to recognize and attack these cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

378 Participants Needed

INO-5401 + INO-9012 + Atezolizumab for Bladder Cancer

Westwood, Kansas
This is a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population is divided into two cohorts: Cohort A: Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with anti-Programmed Death receptor-1/Programmed Death receptor Ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: Participants with locally advanced unresectable or metastatic/recurrent UCa, who are treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in will be performed with up to six participants (safety analysis participants) from cohort A.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

35 Participants Needed

Nitrofurantoin for Urinary Tract Infection

Kansas City, Kansas
The goal of this clinical trial is to learn if the drug Nitrofurantoin (NF) taken as a daily antibiotic, works to treat cystitis compared to electrofulguration (EF) and Nitrofurantoin (NF) daily antibiotic.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Sex:Female

104 Participants Needed

DuoCAR20.19.22-D95 for Non-Hodgkin's Lymphoma

Westwood, Kansas
This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targeting the B cell surface antigens CD19/20/22 following administration of a chemotherapy lymphodepletion regimen in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin's lymphoma (NHL). The overall goals of this study are to estimate maximum tolerated dose (MTD) level, establish the overall safety profile and evaluate initial efficacy of administering duo-CAR-T cell treatment in this patient population.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

54 Participants Needed

SCB-1019T for Respiratory Syncytial Virus

Kansas City, Missouri
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:60 - 85

160 Participants Needed

Clenbuterol for FSHD

Kansas City, Kansas
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

APVO436 + Venetoclax + Azacitidine for AML

Fairway, Kansas
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

39 Participants Needed

Inhaled Ciclesonide for Bronchopulmonary Dysplasia

Kansas City, Missouri
Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:8 - 28

30 Participants Needed

HS135 for Heart Failure and Pulmonary Hypertension

Kansas City, Missouri
A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

30 Participants Needed

Trihexyphenidyl for Cerebral Palsy

Kansas City, Missouri
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:5 - 17

40 Participants Needed

MT-401-OTS for Acute Myeloid Leukemia and Myelodysplastic Syndrome

KAnsas city, Kansas
This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \</= 10% blasts following treatment with an HMA-based therapy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:65+

40 Participants Needed

SynKIR-310 for Non-Hodgkin's Lymphoma

Fairway, Kansas
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

18 Participants Needed

OPN-6602 + Dexamethasone for Multiple Myeloma

Westwood, Kansas
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

130 Participants Needed

High-Dose Radiation + Immunotherapy for Cancer

Kansas City, Kansas
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In patients who have exhausted SoC treatment options.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1

54 Participants Needed

AJ1-11095 for Myelofibrosis

Kansas City, Kansas
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

76 Participants Needed

SC262 for Non-Hodgkin's Lymphoma

Kansas City, Kansas
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

35 Participants Needed

Why Other Patients Applied

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

Negative Pressure Therapy for Surgical Wounds

Kansas City, Kansas
The goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are: * The device-related serious adverse event rate. * Patient post-operative pain as assessed using a validated pain measurement scoring system. * The number and type of adverse events. * The rate of delayed seroma formation. Participants will * Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications. * Undergo a physical exam, an assessment of patient vital signs and routine blood analyses. * Complete an Informed Consent Form if selected to participate in the investigational study. * Be randomly assigned to the different study arms. * Not change the operation of their respective device or to disturb components of their device. * Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device. * Attend two post-operative visits at approximately one month and three months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

SGN-35C for Lymphoma

Fairway, Kansas
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

210 Participants Needed

SRD-001 for Duchenne Muscular Dystrophy

Kansas City, Kansas
This research study is testing whether an experimental drug, called SRD-001, is safe and helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its ability to effectively pump blood to the rest of the body. SRD-001 is a form of gene therapy. The goal of SRD-001 gene therapy is to provide the heart muscle cells with extra copies of the SERCA2a gene so that they can produce more SERCA2a protein to help the heart muscle cells squeeze/contract better. Researchers will compare SRD-001 treated participants with no-treatment participants; all participants will continue to take their current heart medications. All participants will be followed very closely for 2 years and undergo cardiac magnetic resonance imaging of their heart at baseline, year 1 and year 2 along with assessment of upper limb function and lung function. After the 2 years of close follow-up, all participants will roll over into long-term follow-up where they will be called biannually for information on their current medical status.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Sex:Male

12 Participants Needed

CC-97540 for Multiple Sclerosis

Kansas City, Kansas
This trial is testing a new drug called CC-97540 to see if it is safe and effective for people with relapsing or progressive multiple sclerosis. The goal is to find out if it can help manage symptoms or slow down the disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60

120 Participants Needed

NT-112 for Solid Tumors

Fairway, Kansas
This trial tests NT-112, a personalized immune cell treatment, in patients with advanced cancers that have a specific genetic mutation. The treatment boosts the patient's immune cells to target and kill cancer cells. This highly personalized cancer therapy involves giving the patient immune cells that directly attack cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

24 Participants Needed

PGN-EDODM1 for Myotonic Dystrophy

Fairway, Kansas
This trial is testing the safety and tolerability of a drug called PGN-EDODM1, given through an IV, in people with Myotonic Dystrophy Type 1 (DM1). The drug aims to address the underlying issues causing muscle problems in these patients. The study includes initial assessments followed by a period of receiving the drug and monitoring.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60

32 Participants Needed

Revumenib + Chemotherapy for Acute Myeloid Leukemia

Kansas City, Missouri
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective * To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:1 - 30

24 Participants Needed

GLB-001 for Acute Myeloid Leukemia

Kansas City, Kansas
This trial tests a new drug, GLB-001, in patients with certain types of blood cancer that haven't responded to other treatments. The goal is to find out how safe the drug is and what dose works best.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

48 Participants Needed

ZEN003694 + Chemotherapy for Colorectal Cancer

Westwood, Kansas
This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has come back after a period of improvement (relapsed), and that has spread from where it first started (primary site) to other places in the body (metastatic). ZEN003694 is a protein inhibitor that binds to BET proteins. When ZEN003694 binds to BET proteins, it disrupts gene expression. Preventing the expression of certain growth-promoting genes may inhibit proliferation of tumor cells that over-express BET proteins. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Encorafenib is an enzyme inhibitor. It inhibits pathways that are responsible for controlling cell proliferation and survival, which may lead to a decrease in tumor cell proliferation. Both cetuximab and encorafenib have been approved to treat cancer. Adding ZEN003694 to cetuximab and encorafenib may be more effective at treating patients with refractory metastatic colorectal cancer than giving the usual treatment (cetuximab and encorafenib) alone.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

Ketamine for Suicidal Thoughts

Kansas City, Kansas
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

50 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Kansas City, MO pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Kansas City, MO work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Kansas City, MO 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Kansas City, MO is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Kansas City, MO several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Kansas City, MO?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Kansas City, MO?

Most recently, we added Inhaled Ciclesonide for Bronchopulmonary Dysplasia, Nitrofurantoin for Urinary Tract Infection and MT-401-OTS for Acute Myeloid Leukemia and Myelodysplastic Syndrome to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Missouri

Anxiety Clinical Trials in Missouri

Schizophrenia Clinical Trials in Missouri

ADHD Clinical Trials in Missouri

Bipolar Disorder Clinical Trials in Missouri

Multiple Sclerosis Clinical Trials in Missouri

Autism Clinical Trials in Missouri

Treatment Resistant Depression Clinical Trials in Missouri

Borderline Personality Disorder Clinical Trials in Missouri

Social Anxiety Disorder Clinical Trials in Missouri

Parkinson's Disease Clinical Trials in Missouri

Alzheimer's Disease Clinical Trials in Missouri

By Location

Clinical Trials near Saint Louis, MO

Clinical Trials near Kansas City, MO

Clinical Trials near St. Louis, MO

Clinical Trials near Springfield, MO

Clinical Trials near Columbia, MO

Clinical Trials near Cape Girardeau, MO

Clinical Trials near Chesterfield, MO

Clinical Trials near Rolla, MO

Clinical Trials near Saint Joseph, MO

Clinical Trials near Jefferson City, MO

Clinical Trials near Joplin, MO

Clinical Trials near Lee's Summit, MO

Other People Viewed

By Subject

Top Clinical Trials near Kansas City, MO

Top Breast Cancer Clinical Trials near Kansas City, MO

Top Lung Cancer Clinical Trials near Kansas City, MO

17 Glioblastoma Trials near Kansas City, MO

11 Alzheimer's Disease Trials near Kansas City, MO

11 Autism Trials near Kansas City, MO

11 Weight Loss Trials near Kansas City, MO

Top Depression Clinical Trials near Kansas City, MO

Top Clinical Trials near Kansas City, KS

Top Clinical Trials near Joplin, MO

Top Clinical Trials near Florissant, MO

Top Clinical Trials near Bolivar, MO

By Trial

PET Imaging with 64CU-DOTA-ECL1i for Atherosclerosis

Transvaginal Ultrasound Screening for Ovarian Cancer

Telehealth Coaching for Pancreatic Cancer Survivors

DNL593 for Frontotemporal Dementia

Cannabidiol for Opioid Use Disorder and Chronic Pain

Gene Therapy for Glycogen Storage Disease Type Ia

Electrophysiology-Guided Care for Left Bundle Branch Block After TAVI

HoLEP Before Radiation Therapy for Prostate Cancer

Ethanol + Cannabis Effects on DUI

BTKi + Venetoclax for Chronic Lymphocytic Leukemia

GO-203-2C for Acute Myeloid Leukemia

Exercise + Radiation Therapy for Prostate Cancer

Related Searches

Top Kaposi-sarcoma Clinical Trials

Top Afib Clinical Trials

Top Clinical Trials near Glendale, AZ

ChromoSeq for Myelodysplastic Syndrome

Xeltis Graft for Kidney Failure

Immunotherapy + Hormone Therapy for Prostate Cancer

RSI-MRI for Early Detection of Prostate Cancer

AZD5004 for Obesity

Light Therapy for Oral Mucositis

Vaccine Response After CAR-T Therapy for B-Cell Lymphoma

RGX-314 for Age-Related Macular Degeneration

Canagliflozin for Kidney Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial